Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Methods (San Diego, Calif.)
|
December 14, 2005
Methods to measure ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex
Claudine Kraft, Michael Gmachl, Jan-Michael Peters
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 10, 2021
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
Takamasa Koga, Kenichi Suda, Toshio Fujino, et al.
EMBO Molecular Medicine
|
September 26, 2014
Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase
Stefanie Peter, Jennyfer Bultinck, Kevin Myant, et al.
Journal of Medicinal Chemistry
|
July 15, 2024
Chasing Red Herrings: Palladium Metal Salt Impurities Feigning KRAS Activity in Biochemical Assays
Thomas Gerstberger, Helmut Berger, Frank H Büttner, et al.
Molecular Cancer Therapeutics
|
December 23, 2024
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti, et al.
Journal of Medicinal Chemistry
|
October 27, 2022
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS<sup>G12C</sup> Inhibitor
Joachim Bröker, Alex G Waterson, Chris Smethurst, et al.
Biorxiv : the Preprint Server for Biology
|
February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Journal of Medicinal Chemistry
|
March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS
Juergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.
Cancer Discovery
|
August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 24, 2019
Drugging an undruggable pocket on KRAS
Dirk Kessler, Michael Gmachl, Andreas Mantoulidis, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Methods (San Diego, Calif.)
|
December 14, 2005
Methods to measure ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex
Claudine Kraft, Michael Gmachl, Jan-Michael Peters
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 10, 2021
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
Takamasa Koga, Kenichi Suda, Toshio Fujino, et al.
EMBO Molecular Medicine
|
September 26, 2014
Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase
Stefanie Peter, Jennyfer Bultinck, Kevin Myant, et al.
Journal of Medicinal Chemistry
|
July 15, 2024
Chasing Red Herrings: Palladium Metal Salt Impurities Feigning KRAS Activity in Biochemical Assays
Thomas Gerstberger, Helmut Berger, Frank H Büttner, et al.
Molecular Cancer Therapeutics
|
December 23, 2024
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti, et al.
Journal of Medicinal Chemistry
|
October 27, 2022
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS<sup>G12C</sup> Inhibitor
Joachim Bröker, Alex G Waterson, Chris Smethurst, et al.
Biorxiv : the Preprint Server for Biology
|
February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Journal of Medicinal Chemistry
|
March 15, 2021
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS
Juergen Ramharter, Dirk Kessler, Peter Ettmayer, et al.
Cancer Discovery
|
August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 24, 2019
Drugging an undruggable pocket on KRAS
Dirk Kessler, Michael Gmachl, Andreas Mantoulidis, et al.
Page
of 2